Dicellasp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-11-28
Share capital
121 600,00 PLN
Activity description

Dicella is a team of software developers specializing in electronic data capture for clinical trials, offering products such as eCRF, CTMS, eISF/eTMF, and IWRS. They also incorporate technologies like blockchain and artificial intelligence to enhance data protection and support researchers throughout the clinical trial process.

Registered address
ul. Podole 60, 30-394 Kraków, Poland
Website
dicella.comWebsite active
Email
Email address current
Phone
Social media

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 322.19kMedianUSD 133.91kAverageUSD 4.65m
Net profit
This companyUSD 4.33kMedianUSD -54.78AverageUSD 310.10k
Operating costs
This companyUSD 285.49kMedianUSD 175.72kAverageUSD 4.46m
Assets
This companyUSD 1.55mMedianUSD 254.44kAverageUSD 8.12m

Bank accounts

Registered as a VAT taxpayer on 2018-01-05. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Mar 11, 2019Call to creditors

Public aid

32 public aid cases recorded, with a total value of $1,186,162.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$27,727
De minimis aid (in accordance with Commission Regulation 2023/2831)
$303
De minimis aid (in accordance with Commission Regulation 2023/2831)
$0

European Funds

5 projects co-financed from European Funds recorded, with total EU co-financing of $931,172.

ProjectEU co-financing
eCRF+ML diCELLa clinical trials - elektroniczna karta pacjenta wsparta algorytmami uczenia maszynowego
$329.9K
qCELLa- przeprowadzenie prac badawczo-rozwojowych w zakresie analizy zdjęć medycznych z wykorzystaniem komputerów kwantowych.
$482.3K
diCELLa R&D: Budowa centrum badawczo-rozwojowego umożliwiającego rozwój innowacyjnych produktów opartych o sztuczną inteligencje
$47,564

Tenders

5 tenders recorded as contractor: 3 national ($135,034) and 2 EU ($248,514).

SubjectAmount
Zakup, dostawa i wdrożenie systemu informatycznego do zarządzania badaniami klinicznymi (CTMS) oraz zakup dodatkowych licencji systemu amms wraz z wdrożeniem.
$124.3K
Zakup, dostawa i wdrożenie systemu informatycznego do zarządzania badaniami klinicznymi (CTMS) oraz zakup dodatkowych licencji systemu amms wraz z wdrożeniem.
$124.3K
Dostawa, wdrożenie, świadczenie serwisu gwarancyjnego kreatora elektronicznego dzienniczka pacjenta (kreatora EDP) do zdalnego gromadzenia danych w badaniu klinicznym.
$36,628

Authorized Representatives

Aleksandra Kubica Misztal – Management Board Member
Krzysztof Paweł Misztal – President of the Management Board

Manner of representation

In the case of a multi-member management board, the joint action of two members of the management board, or one member of the management board jointly with a commercial proxy, is required to submit declarations of will concerning the rights and obligations.

Ownership

OwnerSharesShare valueStake
Aleksandra Kubica Misztal (40)
950$12,830.9039.0625%
Krzysztof Paweł Misztal (41)
950$12,830.9039.0625%
Voxel S.A.
532$7,185.3121.875%

Aleksandra Kubica Misztal and Krzysztof Paweł Misztal hold a combined 78.1% – the ownership structure indicates family control.

Beneficial owners

Person

Competitors

Name
CTI Clinical Trial And Consulting Services Polandsp. z o.o.
Digital Pathology Team Witold Reznersp. k.
DigitmedS.A.
CCTSsp. z o.o.
Createcsp. z o.o.
TCIsp. z o.o.
Codeit4us Rndsp. z o.o.
Pharmaxi Polandsp. z o.o.
AI Corelabsp. z o.o.
IntelliseqS.A.

Change history

DateEvent
2025-06-05Share capital change
2025-06-05PKD change
2021-06-21Address change
2019-09-20Address change
2019-07-04Share capital change

FAQ

Last updated: 2026-07-22